A brighter future for psoriasis patients in Egypt

The Ministry of Health has approved the first biological treatment for moderate to severe plaque psoriasis, Tremfya (Guselkumab). The drug, manufactured by Jansen, is the first biologic that selectively blocks interleukin (IL)-23 which is considered as the key driver of the immune inflammatory response in psoriasis.